Abstract
Abstract
Chimeric antigen receptor (CAR) T‐cell therapies directed against c
luster of differentiation 19 (
CD19) are a standard of care for relapsed or refractory B‐cell lymphomas. Infection is the leading cause of non‐relapse mortality, and this risk may persist for years after CAR T‐cell receipt. Recipients of CAR T‐cells can present in various clinical settings, and few trials have prospectively assessed prevention and management of infection in this group. This position statement provides Australian and New Zealand clinicians with a rational approach to preventing, investigating and managing infections after CD19‐directed CAR T‐cell therapy for lymphoma.